Sartorius AG
SRT.DE · XETRA
Market closed€193.40€-3.00 (-1.53%)
Key statistics
Previous close€196.40
Open€200.00
Day high€200.00
Day low€193.40
52-week high€208.00
52-week low€145.40
Market cap16.81B
Volume3.57K
Average volume3.99K
P/E ratio40.63
Forward P/E—
EPS4.76
Dividend yield+0.30%
Market context
Why it moved
SRT.DE declined amid broad market weakness driven by a sharp selloff in mega-cap technology stocks, which pulled major indices lower as investor concerns mounted over elevated AI-related capital spending ahead of key tech earnings reports.
What is happening
Recent company-specific developments and publisher coverage.
Select Science · July 1, 2026TechTalk: How to improve lab efficiency and sustainability with Picus® 2 pipettes and consumablesSimply Wall Street · June 25, 2026Is Sartorius (XTRA:SRT3) Undervalued After Stem Cell Media Growth News?Contract Pharma · June 21, 2026Sartorius, LFB Biomanufacturing Expand CollaborationDrug Discovery News · June 3, 2026Sartorius launches Cubis® III balances with built-in compliance and connectivityNews-Medical · March 18, 2026Sartorius launches next-generation platform to boost efficiency in cell therapy productionThe Medicine Maker · November 7, 2014Sartorius Unveils Platform Aimed at Scaling Autologous Cell Therapy Mt Newswire · July 10, 2026Berenberg Ups Sartorius AG Price Target Ahead of Q2 Results; Buy Rating Kept Mt Newswire · June 8, 2026Sartorius Kept at Sell as Mwb Notes 'More Visible' Pharma Capex Risk Mt Newswire · May 26, 2026Sartorius AG Price Target, Estimates Down at AlphaValue/Baader Europe Post-FY26 Guidance Mt Newswire · May 21, 2026Sartorius Opens New Therapy Components Production Centre in Germany Mt Newswire · March 18, 2026Sartorius Price Target Up as Mwb Notes Midterm Targets; Sell Maintained Mt Newswire · March 18, 2026RBC: Sartorius Puts Spotlight on Cash Generation Potential, Long-term Growth Drivers Mt Newswire · March 18, 2026RBC Keeps Sartorius Stedim Biotech at Outperform After Capital Markets Day Mt Newswire · March 17, 2026Sartorius Stedim Biotech Sets Mid-term Revenue Growth Outlook